![](/images/Company_Logo/company_logo_default.png)
Vaccinex Inc (AKA: Vaccinex LP) Profile last edited on: 4/28/2022
CAGE: 1J6F3
UEI: W9DSMAL2EES8
Business Identifier: Novel therapeutic antibodies for neurodegenerative disorders and oncology Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 25
County: Monroe
Congr. District: 25
County: Monroe
Public Profile
With original ties to the University of Rochester and not SBIR involved in some time, Vaccinex, Inc. (NASDAQ: VCNX) is taking a differentiated approach to treating neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D), a key driver of neuroinflammation. Actively in SBIR In the years following founding of the firm-- but not recently -- the companys lead drug candidate, pepinemab, blocks SEMA4D and has potential as a disease-modifying treatment for Huntingtons, Alzheimers and other neurodegenerative diseases. Beyond neurology, Vaccinex has determined that, in combination with checkpoint inhibitors, pepinemab has potential to increase objective responses in oncology. The company additionally intends to leverage its proprietary drug discovery platform, ActivMAb®, to create opportunities for future pipeline expansion and strategic collaborations.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
25-49Revenue Range
2.5M-5MVC funded?
YesPublic/Private
Publicly TradedStock Info
NASDAQ : VCNXIP Holdings
100-149Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2005 | 2 | NIH | $413,049 | |
Project Title: Functional Identification of Cancer Regulators | ||||
2005 | 2 | NIH | $1,358,678 | |
Project Title: Human Monoclonal Antibodies for Bioterrorism Defense | ||||
2005 | 2 | NIH | $599,735 | |
Project Title: New Target Antigens for Prostate Cancer Immunotherapy | ||||
2004 | 1 | NIH | $217,632 | |
Project Title: Monoclonal Antibody Therapy to Combat Osteoporosis | ||||
2004 | 2 | NIH | $433,400 | |
Project Title: A Method to identify upstream regulators of oncogenes |
Key People / Management
Maurice Zauderer -- President
Melinda A Borrello
Deborah Helleson -- Vice President of Business Development / Consultant
R Stan Holland -- Vice President of Finance and CFO
John E Leonard -- SVP Development
Shaun C Martin -- Director, Business Development
Eric C Milner
Mark J Parish
Ernest S Smith -- Vice President of Research and CSO
Raymond E Watkins -- Vice President of Operations
Melinda A Borrello
Deborah Helleson -- Vice President of Business Development / Consultant
R Stan Holland -- Vice President of Finance and CFO
John E Leonard -- SVP Development
Shaun C Martin -- Director, Business Development
Eric C Milner
Mark J Parish
Ernest S Smith -- Vice President of Research and CSO
Raymond E Watkins -- Vice President of Operations
Company News
There are no news available.